Olmesartan: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #96 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Angiotensin receptor blockers]] | |||
[[Category:Antihypertensives]] | |||
Latest revision as of 10:43, 23 May 2026
Olmesartan (medoxomil)
Benicar
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed
Preparations
5, 20, 40 mg tablets
US FDA Max
40 mg/d
Pharmacology
Routes
Oral
Onset
BP effect 1-2 weeks; max at 2-3 weeks
Duration
24 hours
Half-life
~13 hours[1]
Bioavailability
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)[1]
Pregnancy
Contraindicated in pregnancy (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection[1]
Legal status
Rx-only in US
Purported mechanism
Olmesartan medoxomil is a prodrug hydrolyzed to the active selective AT1 angiotensin-II receptor antagonist; blocking AT1 produces vasodilation, decreased aldosterone, and reduced sodium retention without the bradykinin accumulation that drives ACE-inhibitor cough.0 Sprue-like enteropathy with chronic diarrhea and villous atrophy is a well-described class-specific adverse effect first reported with olmesartan in 2013 (FDA safety advisory) and now recognized for the ARB class; reversible on discontinuation[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Benicar (olmesartan medoxomil), Daiichi Sankyo, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021286s044lbl.pdf